OCEA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 May 2024 @ 16:00):

Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation...

Stats
Today's Volume	304 801
Average Volume	7.06M
Market Cap	48.51M
EPS	$-0.390 ( 2023-08-14 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.470
ATR14	$0.00800 (0.57%)

Insider Trading

Date	Person	Action	Amount	type
2023-02-14	Poseidon Bio, Llc	Sell	0	Class A Common Stock, par value $0.0001
2023-02-14	Poseidon Bio, Llc	Sell	18 582 930	Earnout Rights

INSIDER POWER
-100.00
Last 2 transactions
Buy: 0 \| Sell: 18 582 930

Volume Correlation

Long: 0.13 (neutral)

Short: -1.00 (very strong negative)

Signal:(49.078) Neutral

Ocean Biomedical, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ocean Biomedical, Inc. Correlation - Currency/Commodity

0.55
( weak )

0.29
( neutral )

0.00
( neutral )

0.63
( weak )

0.80
( moderate )

-0.32
( neutral )

Ocean Biomedical, Inc. Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$0.0428

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$0.0428

FY	2020
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.0820

FY	2019
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.0115

Financial Reports:

No articles found.

Ocean Biomedical, Inc.

Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island.